SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Malmström Per Uno) "

Sökning: WFRF:(Malmström Per Uno)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersson, Lennart, et al. (författare)
  • Chairmen's summary
  • 2008
  • Ingår i: Scandinavian Journal of Urology and Nephrology, Supplementum. - 0300-8886 .- 1651-2537. ; :218, s. 7-11
  • Tidskriftsartikel (refereegranskat)abstract
    • Several important observations emerge from this 2008 International Consultation "Bladder Cancer from Pathogenesis to Prevention". The following is a brief summary the issues that have been discussed in the articles from the meeting.
  •  
2.
  • Danielsson, Gun, et al. (författare)
  • Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment
  • 2018
  • Ingår i: Scandinavian journal of urology. - TAYLOR & FRANCIS LTD. - 2168-1805. ; 52:5-6, s. 377-384
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Investigate symptoms and how they affect daily life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG) instillations. Materials and methods: Patients treated with BCG were included. After an initial transurethral resection (TURB) followed by a second-look resection, the patients were given an induction course with BCG for 6 weeks followed by maintenance therapy for 2 years. The patients answered a questionnaire before, during and after the treatment. The questionnaire contained questions about specific symptoms combined with bother questions on how each symptom affected patients life. Results: In total, 113 of 116 patients responded to the first questionnaire. Thirty per cent of all patients were bothered by disease-specific symptoms before the start of BCG. Few patients reported fever, haematuria, illness or urinary tract symptoms. No difference in symptoms was found between patients with or without concomitant CIS (carcinoma in situ). Patients younger than 65 years of age reported a greater worry about the symptom burden in the future than those who were older. Patients younger than 65 years reported a decreased level of mental well-being. Conclusion: Patients with bladder cancer T1G2-G3 had disease-specific symptoms present already before the start of the BCG. The burden of symptoms was reduced over time and showed that the bladder might recover. BCG instillations had side-effects that negatively affected the patients well-being. It is important to record the patients baseline bladder and voiding status before as well as during the BCG-instillation period in order to understand symptoms caused by the treatment.
  •  
3.
  • Dansk, Viktor, et al. (författare)
  • Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer cost consequences during outpatient surveillance in Sweden
  • 2016
  • Ingår i: Future Oncology. - 1479-6694 .- 1744-8301. ; 12:8, s. 1025-1038
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: This study explored the cost consequences of introducing hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL BLFC) as an adjunct to white-light flexible cystoscopy compared with white-light flexible cystoscopy alone, for the detection and management of nonmuscle invasive bladder cancer in Sweden.Methods: The model evaluated 231 patients in the outpatient setting after successful initial transurethral resection of the bladder tumor.Results: HAL BLFC introduction across all risk groups resulted in minimal budget impact (+ 1.6% total cost/5 years, or 189 Swedish Krona [SEK] per patient/year), and translated to cost savings in intermediate-and high-risk groups from year 2.Conclusion: HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.
4.
  • Duchek, Milos, et al. (författare)
  • Bacillus Calmette-Guerin Is Superior to a Combination of Epirubicin and Interferon-alpha 2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study
  • 2010
  • Ingår i: European Urology. - 0302-2838. ; 57:1, s. 25-31
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Bacillus Calmette-Guerin (BCG) instillation is regarded as the most effective bladder-sparing treatment for patients with high-grade T1 tumours and carcinoma in situ (CIS). The major problem with this therapy is the side-effects, making maintenance therapy difficult, even impossible, in a proportion of patients. Thus, alternative schedules and drugs have been proposed. Objective: To compare BCG to the combination of epirubicin and interferon-alpha 2b as adjuvant therapy of T1 tumours. Design, setting, and participants: This is a Nordic multicenter, prospective, randomised trial in patients with primary T1 G2-G3 bladder cancer. Initial transurethral resection (TUR) was followed by a second-look resection. Patients were randomised to receive either regimen, given as induction for 6 wk followed by maintenance therapy for 2 yr. Measurements: The drugs were compared with respect to time to recurrence and progression. Also, side-effects were documented. Results and limitations: A total of 250 patients were randomised. At the primary end point, 62% were disease free in the combination arm as opposed to 73% in the BCG arm (p = 0.065). At 24 mo, there was a significant difference in favour of the BCG-treated patients (p = 0.012) regarding recurrence, although there was no difference regarding progression. The subgroup analysis showed that the superiority of BCG was mainly in those with concomitant CIS. In a multivariate analysis of association with recurrence/progression status, significant variables for outcome were type of drug, tumour size, multiplicity, status at second-look resection, and grade. A corresponding analysis was performed separately in the two treatment arms. Tumour size was the only significant variable for BCG-treated patients, while multiplicity, status at second-look resection, and grade were significant for patients treated with the combination. Conclusions: For prophylaxis of recurrence, BCG was more effective than the combination. There were no differences regarding progression and adverse events between the two treatments.
  •  
5.
  • Gårdmark, Truls, et al. (författare)
  • Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001
  • 2006
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - Taylor & Francis. - 0036-5599. ; 40:4, s. 276-282
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. To analyse the management and outcome of patients with Ta T1 urinary bladder cancer in a population-based national database. Material and methods. Between 1997 and 2001, 94% of all newly diagnosed cases of urinary bladder cancer were registered in the Swedish National Bladder Cancer Register. Data were analysed regarding gender, healthcare region, stage and grade for patients with Ta T1 tumours. The choice of initial treatment in different regions was reviewed. Survival was analysed by calculating relative survival. Results. Out of 9859 registered patients, there were 4442 Ta tumours and 2139 T1 tumours. The median age at diagnosis was 72 and 73 years for patients with Ta and T1 tumours, respectively. Seventy-six percent of the patients were men. The choice of treatment varied between different healthcare regions. A significant trend towards an increased use of intravesical therapy was seen over time. Significantly fewer older than younger patients received such therapy. There was also a tendency towards more intensive therapy in men. The bladder cancer relative 5-year survival rate was 93% for Ta and 75% for T1 tumours. Survival was similar for men and women. Conclusions. Our analysis revealed a regional variation in the treatment of bladder cancer. A large group of patients, even those at high risk, were still undertreated. However, the recent publication of guidelines may have contributed to an increased use of intravesical treatment. Urologists tended to treat TaG3 and T1G3 tumours more aggressively than T1G2 tumours. Therapeutic aggressiveness decreased as the age of the patients increased. The survival rate of patients with bladder cancer in Sweden seems to remain at the levels previously reported for the 1980s.
  •  
6.
  •  
7.
  • Häggström, Christel, et al. (författare)
  • Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe).
  • 2017
  • Ingår i: BMJ open. - 2044-6055. ; 7:9
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: To monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).PARTICIPANTS: The SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.FINDINGS TO DATE: Studies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.FUTURE PLANS: The SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.
8.
  • Jahnson, Staffan, et al. (författare)
  • A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden.
  • 2009
  • Ingår i: Scandinavian journal of urology and nephrology. - 1651-2065. ; 43:4, s. 271-6
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To analyse the management of muscle-invasive bladder cancer in a population-based national register, and specifically to investigate the role of curative therapy (i.e. cystectomy or radiotherapy) in relation to patient, tumour and hospital characteristics. MATERIAL AND METHODS: The Swedish Bladder Cancer Register covers more than 90% of all patients in the country who have been diagnosed with such disease since 1997. Results from 1997-2003 were analysed regarding curative-intent treatment given within 3-6 months of diagnosis of muscle-invasive bladder cancer. RESULTS: In total, 3463 patients with clinical T2-T4 bladder cancer were included in the analysis. Of those patients, 1426 (41%) received curative-intent treatment in the form of radiotherapy (285, 20%) or cystectomy (1141, 80%). Male gender, age < 76 years, favourable TNM category and registration at a high-volume hospital were associated with such treatment. Curative-intent treatment was given to significantly more patients registered at high-volume hospitals (1003/2227, 45%) than at low-volume hospitals (423/1235, 34%) (chi(2)=37.7, p<0.00001). Cystectomy was performed more often in those registered at high-volume than at low-volume hospitals (826/2227, 37%, and 316/1235, 26%, respectively, chi(2)=47.3, p<0.00001). CONCLUSIONS: Lower rates of curative-intent treatment were found in patients registered at low-volume than at high-volume facilities, and the same was seen when comparing females with males, and patients aged 76-80 years with younger patients. Since many of these bladder cancer patients were registered at and eventually treated at hospitals handling fewer than 10 such cases annually, it seems desirable to concentrate treatment of this disease at more specialized centres.
  •  
9.
  • Jahnson, Staffan, et al. (författare)
  • Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe)
  • ????
  • Ingår i: Scandinavian journal of urology. - TAYLOR & FRANCIS LTD. - 2168-1805.
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose: To investigate the management of TaG3 tumours of the urinary bladder using nationwide population-based data in relation to the prevailing guidelines, patients characteristics, and outcome. Materials and methods: The Bladder Cancer Data Base Sweden (BladderBaSe), including data from the Swedish National Register for Urinary Bladder Cancer (SNRUBC), was used to study all patients with TaG3 bladder cancer diagnosed from 2008 to 2014. Patients were divided into the following management groups: (1) transurethral resection (TUR) only, (2) TUR and intravesical instillation therapy (IVIT), (3) TUR and second-look resection (SLR), and (4) TUR with both SLR and IVIT. Patient and tumour characteristics and outcome were studied. Results: There were 831 patients (83% males) with a median age of 74 years. SLR was performed more often on younger patients, on men, and less often in the Western and Uppsala/orebro Healthcare regions. IVIT was performed more often with younger patients, with men, in the Western Healthcare region, and less often in the Uppsala/orebro Healthcare region. Death from bladder cancer occurred in 6% of cases within a median of 29 months (0-84 months) and was lower in the TUR/IVIT and TUR/SLR/IVIT groups compared to the other two groups. Conclusion: In the present study, there was, according to the prevailing treatment guidelines, an under-treatment with SLR for older patients, women, and in some healthcare regions and, similarly, there was an under-treatment with IVIT for older patients. Cancer-specific survival and relative survival were lower in the TUR only group compared to the TUR/IVIT and TUR/SLR/IVIT groups.
  •  
10.
  • Jahnson, Staffan, et al. (författare)
  • Swedish National Registry of Urinary Bladder Cancer: : No difference in relative survival over time despite more aggressive treatment
  • 2016
  • Ingår i: Scandinavian journal of urology. - TAYLOR & FRANCIS LTD. - 2168-1805. ; 50:1, s. 14-20
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. The aim of this study was to use the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) to investigate changes in patient and tumour characteristics, management and survival in bladder cancer cases over a period of 15 years. Materials and methods. All patients with newly detected bladder cancer reported to the SNRUBC during 1997-2011 were included in the study. The cohort was divided into three groups, each representing 5 years of the 15 year study period. Results. The study included 31,266 patients (74% men, 26% women) with a mean age of 72 years. Mean age was 71.7 years in the first subperiod (1997-2001) and 72.5 years in the last subperiod (2007-2011). Clinical T categorization changed from the first to the last subperiod: Ta from 45% to 48%, T1 from 21.6% to 22.4%, and T2-T4 from 27% to 25%. Also from the first to the last subperiod, intravesical treatment after transurethral resection for T1G2 and T1G3 tumours increased from 15% to 40% and from 30% to 50%, respectively, and cystectomy for T2-T4 tumours increased from 30% to 40%. No differences between the analysed subperiods were found regarding relative survival in patients with T1 or T2-T4 tumours, or in the whole cohort. Conclusions. This investigation based on a national bladder cancer registry showed that the age of the patients at diagnosis increased, and the proportion of muscle-invasive tumours decreased. The treatment of all tumour stages became more aggressive but relative survival showed no statistically significant change over time.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (22)
Typ av publikation
tidskriftsartikel (151)
forskningsöversikt (8)
annan publikation (6)
konferensbidrag (1)
Typ av innehåll
refereegranskat (138)
övrigt vetenskapligt (28)
Författare/redaktör
Malmström, Per-Uno, (166)
Jahnson, Staffan, (32)
Segersten, Ulrika, (29)
Liedberg, Fredrik, (28)
Malmstrom, Per-Uno, (24)
Gårdmark, Truls (24)
visa fler...
Sherif, Amir, (23)
Wester, Kenneth, (18)
Malmstrom, PU (17)
Hosseini, Abolfazl, (16)
Ströck, Viveka (15)
Holmäng, Sten (13)
Ljungberg, Börje, (11)
Holmang, Sten, (11)
de la Torre, Manuel, (11)
Holmberg, Lars, (10)
Aljabery, Firas, (10)
Malats, Nuria, (10)
Gardmark, Truls, (9)
Wijkström, Hans, (9)
Hagberg, Oskar, (8)
Tolmachev, Vladimir, (8)
Häggström, Christel, (8)
Dyrskjot, Lars (8)
Orntoft, Torben F., (8)
Hermann, Gregers G., (8)
Strock, Viveka, (7)
Jerlström, Tomas (7)
Hemdan, Tammer (7)
Ullén, Anders (7)
Tötterman, Thomas H. (7)
Busch, Christer, (7)
Real, Francisco X., (7)
Gedda, Lars, (6)
Jerlström, Tomas, 19 ... (6)
Rosell, Johan, (6)
Månsson, Wiking (6)
Beukers, Willemien, (6)
Witjes, J Alfred (6)
Mestad, Oddvar (6)
Lundqvist, Hans (5)
Johansson, Robert, (5)
Uhlén, Mathias, (5)
Palou, Joan (5)
Hellsten, Sverker, (5)
Carlsson, Jörgen, (5)
Zwarthoff, Ellen C., (5)
Wijkstrom, Hans, (5)
Algaba, Ferran, (5)
Gontero, Paolo (5)
visa färre...
Lärosäte
Uppsala universitet (152)
Lunds universitet (36)
Umeå universitet (29)
Linköpings universitet (23)
Karolinska Institutet (23)
Göteborgs universitet (10)
visa fler...
Örebro universitet (8)
Kungliga Tekniska Högskolan (2)
Ersta Sköndal Bräcke högskola (2)
visa färre...
Språk
Engelska (147)
Svenska (8)
Odefinierat språk (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (143)
Naturvetenskap (6)
Teknik (4)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy